Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2017

View Archived Issues

XyloCor Therapeutics' XC-001 awarded FDA fast track designation

Rasna Therapeutics provides update on RASP-101

FDA approves Kisqali Femara Co-Pack

resTORbio initiates phase IIb study of RTB-101 to reduce respiratory tract infections in the elderly

Pfizer reviews key developments of first quarter 2017

PaxVax initiates clinical trial program for modernized Ad 4/7 vaccine

FDA authorizes IND application for NANT cancer vaccine clinical trials

RET kinase inhibitor GSK-589 shows promise for IBS treatment

Auris Medical reports results from extension study of AM-101 for tinnitus

STRATOS 1 trial of tralokinumab in severe asthma does not meet primary endpoint

Corvus Pharmaceuticals enters immuno-oncology agreement with Monash University

Apellis Pharmaceuticals granted E.U. orphan drug designation for APL-2 in PNH

FDA approves Bavencio for advanced urothelial carcinoma

Array reports part 2 data from COLUMBUS study of binimetinib and encorafenib in advanced melanoma

Pharnext and Tasly enter strategic agreement

Recro Pharma reports positive topline data from phase III study of intravenous meloxicam

FDA grants orphan drug designation to XmAB-5871

FORUM Pharmaceuticals discovers novel nicotinic alpha7 receptor agonists

TXP Pharma identifies new N-formyl peptide receptor 2 agonists

Novel compounds for parasitic protozoal infections discovered at GlaxoSmithKline

Selvita divulges new MKNK1/MKNK2 inhibitors

Merck & Co. describes novel antituberculosis compounds

Redx Pharma presents data for REDX-08106 as a potent antibacterial compound

IMvigor211 study of Tecentriq in advanced bladder cancer does not meet primary endpoint

Universite de Montreal discloses novel proteinase-activated receptor 4 antagonists

CD26, a marker of hepatic inflammation in hepatitis E virus infection

Clinical benefit seen with upadacitinib tartrate in Crohn's disease patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...